Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Achieve Life Sciences's 3-Year RORE % for the quarter that ended in Mar. 2026 was -6.27%.
The industry rank for Achieve Life Sciences's 3-Year RORE % or its related term are showing as below:
STU:SP4P's 3-Year RORE % is ranked better than 58.56% of 1291
companies
in the Biotechnology industry
Industry Median: -11.44
vs STU:SP4P: -6.27
Achieve Life Sciences (STU:SP4P) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Achieve Life Sciences 3-Year RORE % Related Terms
Achieve Life Sciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Achieve Life Sciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:SP4P vs STTK, CRMD, EIKN: 3-Year RORE % Comparison
For the Biotechnology subindustry, Achieve Life Sciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Achieve Life Sciences 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Achieve Life Sciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Achieve Life Sciences (STU:SP4P) has a 3-Year RORE % of -6.27 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Achieve Life Sciences and its competitors. According to the industry distribution chart, Achieve Life Sciences ranks #535 out of 1291 companies in the Biotechnology industry, placing it in the top 41.4%.
Is Achieve Life Sciences' 3-Year RORE % too high?
Achieve Life Sciences' current 3-Year RORE % is -6.27. Based on the distribution chart, Achieve Life Sciences ranks #535 out of 1291 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Achieve Life Sciences has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' 3-Year RORE % compare to STTK and CRMD?
According to the Biotechnology industry distribution chart, Achieve Life Sciences ranks #535 out of 1291 companies for 3-Year RORE %. This puts Achieve Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Achieve Life Sciences and its competitors. Achieve Life Sciences's current 3-Year RORE % is -6.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current 3-Year RORE % of -6.27. The current 3-Year RORE % is -6.27. Achieve Life Sciences' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current 3-Year RORE % is -6.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
39GF Score
Get the complete analysis for STU:SP4P
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SP4P has been successfully added to your 
